OR WAIT null SECS
Advancements in personalized medicine and other innovations are transforming the way dosage forms are viewed.
This study aimed to develop a taste-masked drug resin complex using the ion exchange resin Kyron T-114.
Novel genetic engineering technologies are transforming the design and manufacture of bispecific antibodies, which are emerging as a promising new class of biologics.
February 23, 2012
Pfizer has signed an agreement with the Chinese biopharmaceutical company Zhejiang Hisun Pharmaceuticals with the objective of establishing a $545-million joint venture to develop and commercialize branded generic medicines in both China and the global market.
February 17, 2012
PDA organizes this conference to address the technical and regulatory issues related to parenteral packaging. Chemical, physical and microbiological aspects will be considered and current regulatory challenges will be discussed. Two Training Courses on Container Closure Development or Selection and Utilization of Glass Containers in Pharmaceutical Packaging will be given.
February 15, 2012
The author discusses the relative advantages and disadvantages of lyophilization in vials and dual-chamber systems.
February 02, 2012
A nickel's worth of free advice to the competition could come at the expense of your bottom line.
Debottlenecking downstream mAb purification.
Experts discuss solutions for filter bacterial retention and related challenges. Contains online bonus material.
January 19, 2012
The generic-drugs market is poised to experience strong growth as key blockbuster products go off patent, but companies looking to benefit from this will have to be careful about the product segments where they compete, according to a report from Frost & Sullivan.
January 12, 2012
The pharmaceutical majors advance vaccines for the developing world.
January 02, 2012
The authors designed an upper punch with a removable punch tip to determine a tablet formulation's propensity to stick by weighing the mass of powder adhered to the punch tip.
Challenges remain, particularly for early-stage biopharmaceutical companies.